Transarterial chemoembolization alone and in combination with other therapies: A comparative study in an animal HCC model

European Radiology

Volumn 15, Issue 1, 2005, Pages 127-133

  Maataoui, Adel ^a   Qian, J ^a   Vossoughi, D ^a   Khan, M F ^a   Oppermann, E ^a   Bechstein, W O ^a   Vogl, T J ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Hepatocellular carcinoma; Liver; Transarterial chemoembolization

Indexed keywords

ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 2; IODINATED POPPYSEED OIL; MITOMYCIN C; PICIBANIL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTERY CATHETERIZATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CHEMOEMBOLIZATION; CLINICAL PROTOCOL; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; GASTRODUODENAL ARTERY; LAPAROTOMY; LIVER CELL CARCINOMA; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, INBRED STRAINS;

EID: 12144271243     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-004-2517-8     Document Type: Article

References (52)

1. Cha C, DeMatteo RP, Blumgart LH (2002) Surgery and ablative therapy for hepatocellular carcinoma. J Clin Gastroenterol 35(5 Suppl 2):S130-S137 10.1097/00004836-200211002-00009
2. Tang ZY (1998) Treatment of hepatocellular carcinoma. Digestion 59(5):556-562 10.1159/000007531
3. Alsowmely AM, Hodgson HJ (2002) Non-surgical treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 16(1):1-15
4. Durand F, Belghiti J (2002) Liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 49(43):47-52 11941982
5. Poon RT et al (2002) Locoregional therapies for hepatocellular carcinoma: A critical review from the surgeon's perspective. Ann Surg 235(4):466-486 10.1097/00000658-200204000-00004
6. Denys AL et al (2003) Radio-frequency tissue ablation of the liver: In vivo and ex vivo experiments with four different systems. Eur Radiol 13(10):2346-2352 10.1007/s00330-003-1970-0
7. Lee JM et al (2004) Combined treatment of radiofrequency ablation and acetic acid injection: An in vivo feasibility study in rabbit liver. Eur Radiol 14(7):1303-1310 14625783
8. Buscarini E, Buscarini L (2004) Radiofrequency thermal ablation with expandable needle of focal liver malignancies: Complication report. Eur Radiol 14(1):31-37 10.1007/s00330-003-1990-9
9. Sturm JW et al (2001) Locally ablative therapies of hepatocellular carcinoma. Onkologie 24(Suppl 5):35-45 10.1159/000055185
10. Achenbach T et al (2002) Chemoembolization for primary liver cancer. Eur J Surg Oncol 28(1):37-41 10.1053/ejso.2001.1181
11. Llovet JM et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359(9319):1734-1739 10.1016/S0140-6736(02)08649-X
12. Vogl TJ et al (2000) Transarterial chemoembolization for hepatocellular carcinoma: Volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology 214(2):349-357 1:STN:280:DC%2BD3c7jvVKnug%3D%3D
13. Lin DY, Lin SM, Liaw YF (1997) Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12(9-10):S319-S328 1:CAS:528:DyaK2sXnvFKqurw%3D
14. Yoshida T et al (2001) Appraisal of transarterial immunoembolization for hepatocellular carcinoma: A clinicopathologic study. J Clin Gastroenterol 32(1):59-65 10.1097/00004836-200101000-00014
15. Mugitani T et al (1998) TNP-470 inhibits collateralization to complement the anti-tumour effect of hepatic artery ligation. Br J Cancer 77(4):638-642 1:CAS:528:DyaK1cXksFKjtr0%3D
16. Zheng C, Feng G, Liang H (1998) Bletilla striata as a vascular embolizing agent in interventional treatment of primary hepatic carcinoma. Chin Med J (Engl) 111(12):1060-1063 1:STN:280:DC%2BD3M7mt12gtA%3D%3D
17. Yang R et al (1992) A reproducible rat liver cancer model for experimental therapy: Introducing a technique of intrahepatic tumor implantation. J Surg Res 52(3):193-198 10.1016/0022-4804(92)90072-8
18. Trubenbach J et al (2000) Growth characteristics and imaging properties of the morris hepatoma 3924A in ACI rats: A suitable model for transarterial chemoembolization. Cardiovasc Intervent Radiol 23(3):211-217 10.1007/s002700010045
19. Fournier LS et al (2004) Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent. Eur Radiol 14:2125-2133 15503038
20. Klein D et al (2004) Quantitative dynamic contrast-enhanced sonography of hepatic tumors. Eur Radiol 14(6):1082-1091 10.1007/s00330-004-2299-z
21. Nicolau C et al (2004) Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: Correlation with cellular differentiation. Eur Radiol 14(6):1092-1099 10.1007/s00330-004-2298-0
22. Koda M et al (2004) Qualitative assessment of tumor vascularity in hepatocellular carcinoma by contrast-enhanced coded ultrasound: comparison with arterial phase of dynamic CT and conventional color/power Doppler ultrasound. Eur Radiol 14(6):1100-1108 10.1007/s00330-003-2172-5
23. Kwak HS, Lee JM, Kim CS (2004) Preoperative detection of hepatocellular carcinoma: Comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol 14(3):447-457 10.1007/s00330-003-2070-x
24. Carlsson G, Gullberg B, Hafstrom L (1983) Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 105(1):20-23 10.1007/BF00391826
25. Choi BI et al (1992) Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology 182(3):709-713 1:STN:280:By2C2Mbjs1Y%3D
26. Pacella CM et al (2001) Hepatocellular carcinoma: Long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology 219(3):669-678 1:STN:280:DC%2BD3M3ps1ykug%3D%3D
27. Koda M et al (2001) Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: A randomized control study. Cancer 92(6):1516-1524 10.1002/1097-0142(20010915)92:6<1516::AID-CNCR1477>3.0.CO;2-I
28. Bloomston M et al (2002) Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 68(9):827-831 12356160
29. Qian J et al (2003) Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. World J Gastroenterol 9(1):94-98 1:CAS:528:DC%2BD3sXht1aiurc%3D
30. Uehara K et al (2002) Systemic administration of liposome-encapsulated OK-432 prolongs the survival of rats with hepatocellular carcinoma through the induction of IFN-gamma-producing hepatic lymphocytes. J Gastroenterol Hepatol 17(1):81-90 10.1046/j.1440-1746.2002.02675.x
31. Nio Y et al (1999) Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br J Cancer 80(5-6):775-785 10.1038/sj.bjc.6690421
32. Oka M et al (1994) Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: Preliminary results. Cancer Immunol Immunother 38(3):194-200 10.1007/s002620050054
33. Kanai T et al (1994) New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases. Cancer Chemother Pharmacol 33(Suppl):S48-S54 8137485
34. Okuno K et al (1996) IL-2 perfusion to the liver augments the hepatic extraction rate of accompanying anticancer drugs. Surg Today 26(8):662-664 10.1007/BF00311678
35. Okuno K et al (1999) Intrahepatic interleukin-2 with chemotherapy for unresectable liver metastases: A randomized multicenter trial. Hepatogastroenterology 46(26):1116-1121 1:CAS:528:DyaK1MXjs1aksLg%3D
36. Watanabe D et al (1995) Antitumor effects of intraarterial infusion of tumor necrosis factor/lipiodol emulsion on hepatic tumor in rabbits. Oncology 52(1):76-81 1:CAS:528:DyaK2MXkt1CgtL4%3D
37. Yang R et al (1995) Experimental liver cancer: Improved response after hepatic artery ligation and infusion of tumor necrosis factor-alpha and interferon-gamma. Surgery 118(4):768-72 (discussion 772-774) 1:STN:280:BymD3cnjvVE%3D
38. Westphal JR, Ruiter DJ, De Waal RM (2000) Anti-angiogenic treatment of human cancer: Pitfalls and promises. Int J Cancer 86(6):870-873 1:CAS:528:DC%2BD3cXksFSqu78%3D
39. Keshet E, Ben-Sasson SA (1999) Anticancer drug targets: Approaching angiogenesis. J Clin Invest 104(11):1497-1501 1:CAS:528:DyaK1MXnvF2nt7g%3D
40. Tomanek RJ, Schatteman GC (2000) Angiogenesis: New insights and therapeutic potential. Anat Rec 261(3):126-135 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4
41. Folkman J (1996) New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A(14):2534-2539 10.1016/S0959-8049(96)00423-6
42. Drixler TA et al (2000) Angiogenesis and surgery: From mice to man. Eur J Surg 166(6):435-446 10.1080/110241500750008745
43. O'Reilly MS (2002) The combination of antiangiogenic therapy with other modalities. Cancer J 8(Suppl 1):S89-S99 12075706
44. Kim YB, Park YN, Park C (2001) Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 38(2):160-166 10.1046/j.1365-2559.2001.01064.x
45. Ogawa H et al (2000) Combined treatment with TNP-470 and 5-fluorouracil effectively inhibits growth of murine colon cancer cells in vitro and liver metastasis in vivo. Oncol Rep 7(3):467-472 1:CAS:528:DC%2BD3cXjtVOjtb4%3D
46. Figg WD et al (1997) The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 17(1):91-97 1:CAS:528:DyaK2sXisVagsb8%3D
47. Yanai S et al (1995) Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma. Pharm Res 12(5):653-657 10.1023/A:1016243105622
48. Yanai S et al (1994) Antitumor activity of a medium-chain triglyceride solution of the angiogenesis inhibitor TNP-470 (AGM-1470) when administered via the hepatic artery to rats bearing Walker 256 carcinosarcoma in the liver. J Pharmacol Exp Ther 271(3):1267-1273 1:CAS:528:DyaK2MXislelt7s%3D
49. Wang X et al (2002) Inhibitory effect of endostatin expressed by human liver carcinoma SMMC7721 on endothelial cell proliferation in vitro. World J Gastroenterol 8(2):253-257 1:CAS:528:DC%2BD38Xjs1Knsr4%3D
50. O'Reilly MS et al (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277-285 10.1016/S0092-8674(00)81848-6
51. Jiang YF, Yang ZH, JQ Hu (2000) Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol 6(1):61-65 11819524
52. te Velde EA et al (2002) Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 89(10):1302-1309 10.1046/j.1365-2168.2002.02183.x